BioAge Labs Posts Q3 2026 Net Loss of $33.5 Million; QUELL-CV Fully Enrolled
BioAge Labs reported Q3 2026 revenue of $0.3M and a net loss of $33.5M, or $0.73 per share. Cash reserves totaled $352.3M, expected to last through 2029. Key milestones include completing enrollment in the QUELL-CV trial and dosing the first participant in QUELL-DME. R&D expenses rose to $30.2M from $18.5M year-over-year.
How this was made

The 30-second read
Why it matters
The loss widens significantly year‑over‑year, indicating short‑term pressure but long‑term potential from pipeline milestones.
Market read
Primary micro‑cap earnings disclosure; new financials may drive short‑term price movement.
What to watch
Potential upside from upcoming QUELL-CV topline data in Q4 2026 and IND submission by year‑end.
Background
Quarterly earnings release for BioAge Labs, a Nasdaq‑listed biotech focused on aging therapeutics.
Ticker impact
BioAge Labs reported Q3 2026 results with a net loss of $33.5M and $0.3M revenue, the first disclosure of these figures.
likely pressure as investors price in the widening loss and modest revenue
Quarterly earnings are the first report of the numbers; loss exceeds prior period and revenue is minimal, prompting potential sell‑off.
Market effects
Biotech sector may see modest caution as a micro‑cap reports a larger-than‑expected loss.
Limited to U.S. small‑cap biotech investors.
Minimal global impact.
Counterpoint
The cash runway to 2029 could support future upside if upcoming trial data are positive.
Key entities
- companyBioAge Labs Inc.
Nasdaq‑listed biotech reporting Q3 2026 results.